-
公开(公告)号：EP0533517A1
公开(公告)日：1993-03-24
申请号：EP92402319.5
申请日：1992-08-20
发明人： Tsukioka, Daisuke , Yoshimura, Kiyoshi , Oshima, Haruyuki , Soma, Gen-Ichiro , Mizuno, Den'Ichi
IPC分类号： A61K31/715 , C12P19/04
CPC分类号： C12P19/04 , A61K31/715 , Y10S435/822 , Y10S514/885
摘要： Novel antiwithdrawal agents and veterinary antiwithdrawal agents are disclosed which contain LPS representative of which having the following physical properties:
LPS1
Dominant molecular weight: 5,000 ± 1,000 as determined by SDS-PAGE method
Phosphorus number: 2 ± 1 / 5,O00 (m-w.)
Hexosamine number: 9 ± 1 / 5,000 (m.w.)
KDO number: 2 ± 1 / 5,000 (m.w.)
LPS2
Dominant molecular weight: 6,500: ± 2,500 as determined by SDS-PAGE method
Phosphorus number: 1 to 2 / 5,000 (m.w.)
Hexosamine number: 7 ± 1 / 5,000 (m.w.)
KDO number: 1 to 2 / 5,000 (m.w.)
LPS3
Dominant molecular weight: 6,500 ± 2,500 as determined by SDS-PAGE method
Phosphorus number: 2 ± 1 / 5,000 (m.w.)
Hexosamine number: 5 ± 1 / 5,000 (m.w.)
KDO number: 2 ± 1 / 5,000 (m.w.)摘要翻译： 公开了含有代表具有以下物理性质的LPS的新型抗抽出剂和兽用抗抽穗剂：LPS1主要分子量：5,000 +/- 1,000，通过SDS-PAGE法测定磷数：2 +/- 1 / 5,000 （mw。）己糖胺数：9 +/- 1 / 5,000（mw）KDO数：2 +/- 1 / 5,000（mw）LPS2主要分子量：6,500：+/- 2,500，通过SDS-PAGE法测定磷数 ：1〜2 / 5,000（mw）己糖胺数：7 +/- 1 / 5,000（mw）KDO数：1〜2 / 5,000（mw）LPS3主要分子量：6,500 +/- 2,500，通过SDS-PAGE法测定 磷数：2 +/- 1 / 5,000（mw）己糖胺数：5 +/- 1 / 5,000（mw）KDO数：2 +/- 1 / 5,000（mw）e
-
12.发明公开Anti-diabetic agents and veterinary anti-diabetic agents 失效Antidiabetikafürhumane undtierärztlicheAnwendung。
公开(公告)号：EP0462022A2
公开(公告)日：1991-12-18
申请号：EP91401623.3
申请日：1991-06-17
发明人： SOMA, GEN'ICHIRO , YOSHIMURA, KIYOSHI , TSUKIOKA, DAISUKE , MIZUNO, DEN'ICHI, , OSHIMA, HARUYUKI
CPC分类号： A61K36/06 , A61K36/02 , A61K36/07 , A61K36/899 , Y02A50/473 , A61K2300/00
摘要： An anti-diabetic composition comprising an effective amount of at least one member of LPS whose macrophage activation ED₅₀ is 0.4 - 100 ng/ml of culture solution in terms of its limulus test-positive LPS content observed on a sigmoid curve prepared by determining the ability of the LPS to activate the TNF productivity of macrophage cultured in vitro, and plotting the macrophage activation abillty (%) along the axis of ordinate wherein the ability is estimated to be 0 % in the case where it corresponds to the quantity of TNF produced by macrophage with no LPS added thereto, and 100 % is assigned to the macrophage activation ability which provides the maximal and constant quantity of TNF produced by the macrophage and plotting the limulus test-positive LPS content of the LPS along the axis of abscissa on a logarithmic scale, in admixture with a pharmaceutically or veterinarily acceptable carrier, such that when administered to an animal, diabetes mellitus of said animal is prevented or cured; and
a method of treating diabetes mellitus of an animal comprising administration to said animal an amount of the above composition effective to prevent or cure the diabetes mellitus of said animal.摘要翻译： 一种抗糖尿病组合物，其包含有效量的至少一种LPS成分，其巨噬细胞活化ED 50为0.4-100ng / ml培养液，其鲎试验阳性LPS含量在通过测定能力制备的乙状曲线上观察到 的LPS以激活体外培养的巨噬细胞的TNF生产力，并绘制沿纵坐标轴的巨噬细胞活化能力（％），其中在对应于由TNFα产生的TNF的量的情况下，该能力估计为0％ 没有添加LPS的巨噬细胞，100％被赋予巨噬细胞活化能力，其提供由巨噬细胞产生的TNF的最大和恒定量，并沿着横坐标绘制LPS的鲎试验阳性LPS含量为对数 与药物或兽医学上可接受的载体混合，使得当施用于动物时，预防所述动物的糖尿病或c ured; 以及治疗动物糖尿病的方法，包括向所述动物施用一定量的有效预防或治愈所述动物糖尿病的上述组合物。
-
公开(公告)号：EP0462020A2
公开(公告)日：1991-12-18
申请号：EP91401621.7
申请日：1991-06-17
CPC分类号： A61K36/02 , A61K36/06 , A61K36/07 , A61K36/899 , Y02A50/473 , A61K2300/00
摘要： An anti-herpes composition comprising an effective amount of at l east one member of LPS whose macrophage activation ED₅₀ is 0.4 - 100 ng/ml of culture solution in terms of its limulus test-positive LPS content observed on a sigmoid curve prepared by determining the ability of the LPS to activate the TNF productivity of macrophage cultured in vitro , and plotting the macrophage activation ability (%) along the axis of ordinate wherein the ability is estimated to be 0 % in the case where it corresponds to the quantity of TNF produced by macrophage with no LPS added thereto, and 100 % is assigned to the macrophage activation ability which provides the maximal and constant quantity of TNF produced by the macrophage and plotting the limulus test-positive LPS content of the LPS along the axis of abscissa on a logarithmic scale, in admixture with a pharmaceutically or veterinarily acceptable carrier, such that when administered to an animal, herpes of said animal is cured; and
a method of treating herpes of an animal comprising administration to said animal an amount of the above composition effective to cure the herpes of said animal.摘要翻译： 一种抗疱疹组合物，其包含有效量的至少一种LPS的成员，其巨噬细胞活化ED 50为0.4-100ng / ml培养液，其鲎试验阳性LPS含量在通过测定能力制备的乙状曲线上观察到 的LPS以激活体外培养的巨噬细胞的TNF生产力，并绘制沿纵坐标轴的巨噬细胞活化能力（％），其中在对应于由TNFα产生的TNF的量的情况下，该能力估计为0％ 没有添加LPS的巨噬细胞，100％被赋予巨噬细胞活化能力，其提供由巨噬细胞产生的TNF的最大和恒定量，并且沿着横坐标绘制LPS的鲎试验阳性LPS含量为对数 与药学或兽医学上可接受的载体混合，使得当施用于动物时，所述动物的疱疹被固化; 以及治疗动物疱疹的方法，包括向所述动物施用一定量的上述有效治愈所述动物疱疹的组合物。
-
公开(公告)号：EP3296308A1
公开(公告)日：2018-03-21
申请号：EP16780046.5
申请日：2016-04-12
发明人： SUZUKI, Takanao , KATO, Daisuke
IPC分类号： C07H13/06 , A61K8/31 , A61K8/73 , A61Q1/02 , A61Q1/04 , A61Q1/10 , A61Q1/14 , A61Q5/12 , A61Q19/00 , C08B30/18
CPC分类号： A61K8/73 , A61K8/31 , A61Q1/02 , A61Q1/04 , A61Q1/08 , A61Q1/10 , A61Q5/00 , A61Q19/00 , A61Q19/10 , C07H13/06 , C08B30/18
摘要： A dextrin fatty acid ester is provided in which the average degree of glycopolymerization of the dextrin is 3-100. The fatty acid comprises one or more linear C14-18 saturated fatty acids, and one or more branched C14-18 saturated fatty acids. The molar fraction of the linear saturated fatty acid in the fatty acid is 0.75-0.95, and the average degree of substitution of the fatty acid per glucose unit is 1.5-2.0.
摘要翻译： 提供一种糊精脂肪酸酯，其中糊精的糖聚合平均度为3〜100。 脂肪酸包含一种或多种线性C 14-18饱和脂肪酸和一种或多种支化C 14-18饱和脂肪酸。 脂肪酸中直链饱和脂肪酸的摩尔分数为0.75-0.95，每个葡萄糖单元的脂肪酸的平均取代度为1.5-2.0。
-
公开(公告)号：EP0736545B1
公开(公告)日：2003-01-22
申请号：EP96105259.4
申请日：1996-04-02
发明人： Suzuki, Takanao , Amano, Isaburo , Chiba, Koji , Tofukuji, Ruka
-
16.发明公开
公开(公告)号：EP0736545A2
公开(公告)日：1996-10-09
申请号：EP96105259.4
申请日：1996-04-02
发明人： Suzuki, Takanao , Amano, Isaburo , Chiba, Koji , Tofukuji, Ruka
CPC分类号： C08B30/18 , A61K8/06 , A61K8/732 , A61K2800/43 , A61Q1/02 , A61Q1/06 , A61Q1/10 , A61Q19/00 , C08B31/04 , C09D5/04 , C09D11/03
摘要： Disclosed are a dextrin ester of fatty acids in which dextrin has an average saccharide polymerization degree of 3 to 150, the fatty acids comprise a straight chain fatty acid having 8 to 22 carbon atoms and at least one fatty acid selected from the group consisting of branched fatty acids having 4 to 26 carbon atoms, unsaturated fatty acids having 6 to 30 carbon atoms and straight chain saturated fatty acids having 6 or less carbon atoms, and the substitution degree of fatty acids per glucose unit is 1.0 to 3.0; and a gelling agent, a composition and a base comprising the ester, the ester being excellent in thixotropic property, moisture retaining property, emulsifiability, adhesion and dispersibility, and therefore suitably used for cosmetics, printing ink, coatings, etc.
摘要翻译： 公开了糊精的平均糖聚合度为3〜150的脂肪酸糊精酯，脂肪酸包含碳原子数为8〜22的直链脂肪酸和选自支链的脂肪酸的至少一种脂肪酸 碳原子数为4〜26的脂肪酸，碳原子数为6〜30的不饱和脂肪酸和碳原子数为6以下的直链饱和脂肪酸，每个葡萄糖单元的脂肪酸取代度为1.0〜3.0， 胶凝剂，组合物和包含该酯的基质，该酯具有优异的触变性，保湿性，乳化性，粘合性和分散性，因此适合用于化妆品，印刷油墨，涂料等。
-
公开(公告)号：EP0462022A3
公开(公告)日：1992-04-29
申请号：EP91401623.3
申请日：1991-06-17
发明人： SOMA, GEN'ICHIRO , YOSHIMURA, KIYOSHI , TSUKIOKA, DAISUKE , MIZUNO, DEN'ICHI, , OSHIMA, HARUYUKI
CPC分类号： A61K36/06 , A61K36/02 , A61K36/07 , A61K36/899 , Y02A50/473 , A61K2300/00
摘要： An anti-diabetic composition comprising an effective amount of at least one member of LPS whose macrophage activation ED₅₀ is 0.4 - 100 ng/ml of culture solution in terms of its limulus test-positive LPS content observed on a sigmoid curve prepared by determining the ability of the LPS to activate the TNF productivity of macrophage cultured in vitro, and plotting the macrophage activation abillty (%) along the axis of ordinate wherein the ability is estimated to be 0 % in the case where it corresponds to the quantity of TNF produced by macrophage with no LPS added thereto, and 100 % is assigned to the macrophage activation ability which provides the maximal and constant quantity of TNF produced by the macrophage and plotting the limulus test-positive LPS content of the LPS along the axis of abscissa on a logarithmic scale, in admixture with a pharmaceutically or veterinarily acceptable carrier, such that when administered to an animal, diabetes mellitus of said animal is prevented or cured; and
a method of treating diabetes mellitus of an animal comprising administration to said animal an amount of the above composition effective to prevent or cure the diabetes mellitus of said animal.-
公开(公告)号：EP0462021A3
公开(公告)日：1992-04-29
申请号：EP91401622.5
申请日：1991-06-17
发明人： Soma, Gen'Ichiro , Yoshimura, Kiyoshi , Tsukioka, Daisuke , Mizuno, Den'Ichi , Oshima, Haruyuki
CPC分类号： A61K36/02 , A61K36/06 , A61K36/07 , A61K36/899 , A61K2300/00
摘要： A cholesterol-lowering composition comprising an effective amount of at least one member of LPS whose macrophage activation ED₅₀ is 0.4 - 100 ng/ml of culture solution in terms of its limulus test-positive LPS content observed on a sigmoid curve prepared by determining the ability of the LPS to activate the TNF productivity of macrophage cultured in vitro , and plotting the macrophage activation ability (%) along the axis of ordinate wherein the ability is estimated to be 0 % in the case where it corresponds to the quantity of TNF produced by macrophage with no LPS added thereto, and 100 % is assigned to the macrophage activation ability which provides the maximal and constant quantity of TNF produced by the macrophage and plotting the limulus test-positive LPS content of the LPS along the axis of abscissa on a logarithmic scale, in admixture with a pharmaceutically or veterinarily acceptable carrier, such that when administered to an animal, high cholesterol level of said animal is prevented or cured; and
a method of treating high cholesterol level of an animal comprising administration to said animal an amount of the above composition effective to prevent or cure the high cholesterol level of said animal.-
公开(公告)号：EP0462020A3
公开(公告)日：1992-04-29
申请号：EP91401621.7
申请日：1991-06-17
CPC分类号： A61K36/02 , A61K36/06 , A61K36/07 , A61K36/899 , Y02A50/473 , A61K2300/00
摘要： An anti-herpes composition comprising an effective amount of at l east one member of LPS whose macrophage activation ED₅₀ is 0.4 - 100 ng/ml of culture solution in terms of its limulus test-positive LPS content observed on a sigmoid curve prepared by determining the ability of the LPS to activate the TNF productivity of macrophage cultured in vitro , and plotting the macrophage activation ability (%) along the axis of ordinate wherein the ability is estimated to be 0 % in the case where it corresponds to the quantity of TNF produced by macrophage with no LPS added thereto, and 100 % is assigned to the macrophage activation ability which provides the maximal and constant quantity of TNF produced by the macrophage and plotting the limulus test-positive LPS content of the LPS along the axis of abscissa on a logarithmic scale, in admixture with a pharmaceutically or veterinarily acceptable carrier, such that when administered to an animal, herpes of said animal is cured; and
a method of treating herpes of an animal comprising administration to said animal an amount of the above composition effective to cure the herpes of said animal.-
20.发明公开NOVEL DEXTRIN FATTY ACID ESTER THAT DOES NOT CAUSE GELATION OF LIQUID OIL, AND USES THEREOF 有权新的，而不是为液态油凝胶化领先糊精脂肪酸酯及其应用
公开(公告)号：EP2537865A1
公开(公告)日：2012-12-26
申请号：EP11744414.1
申请日：2011-02-16
发明人： KOIKE, Hideaki , SUZUKI, Takanao , TSUKIOKA, Daisuke , MIYAGAWA, Satsuki , TOMITA, Yuriko , IGARASHI, Keiji
IPC分类号： C08B31/04 , A61K8/60 , A61K8/73 , A61K47/26 , A61K47/36 , A61Q1/10 , A61Q1/12 , A61Q3/02 , A61Q5/00 , A61Q17/04 , A61Q19/00 , C07H13/06 , C09D7/12 , C09D11/00 , C09D201/00 , C11C3/04
CPC分类号： C08B31/04 , A61K8/73 , A61K2800/10 , A61Q19/00 , C07H13/06 , C08B30/18 , C09D7/45 , C09D11/14 , C11C3/00
摘要： An object of the present invention is to provide novel dextrin fatty acid ester that is excellent in tackiness and useful as a base for cosmetics and the like. The novel dextrin fatty acid ester is prepared by esterification between dextrin and fatty acids, wherein the dextrin has an average degree of glucose polymerization of 3 to 150; the fatty acids comprise more than 50 mol% and 100 mol% or less, based on the total amount of the fatty acids, of one or more saturated branched fatty acids having 4 to 26 carbon atoms, and 0 mol% or more and less than 50 mol%, based on the total amount of the fatty acids, of one or more fatty acids selected from the group consisting of saturated linear fatty acids having 2 to 22 carbon atoms, unsaturated linear or branched fatty acids having 6 to 30 carbon atoms, and saturated or unsaturated cyclic fatty acids having 6 to 30 carbon atoms; and the degree of substitution by the fatty acids is 1.0 to 3.0 per glucose unit.
摘要翻译： 本发明的一个目的是提供新的糊精脂肪酸酯那样具有优异的粘着性并可用作化妆品的基等。 新颖的糊精脂肪酸酯是由糊精与脂肪酸的酯化来制备，worin糊精平均具有度为3〜150葡萄糖聚合; 所述脂肪酸包含超过50摩尔％且100摩尔％以下，基于所述脂肪酸具有4-10至26个碳原子的一种或多种饱和的支链脂肪酸，总金额，和0摩尔％以上且小于 50摩尔％，基于从选自由具有2至22个碳原子，不饱和的直链的具有6至30个碳原子的饱和直链脂肪酸或支链脂肪酸的脂肪酸的一种或多种脂肪酸，总金额， 和具有6至30个碳原子的饱和或不饱和的环状脂肪酸; 和取代的由脂肪酸的程度为1.0〜3.0每个葡萄糖单元。
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.011 秒)
